Most Read Articles
Jairia Dela Cruz, 5 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.

Male breast cancer: Lack of awareness and embarrassment delay presentation

Natalia Reoutova
27 Mar 2020

A Hong Kong study of 56 male breast cancer patients highlights lack of knowledge and embarrassment as key factors in delays in seeking medical attention.

The mean duration from symptom onset to first consultation was 12.4 months (range, 1–120 months). Six patients (10.7 percent) presented with distant metastases at the time of diagnosis and received palliative systemic treatment only; 38 patients (67.8 percent) were node-positive. Over 90 percent of patients expressed various degrees of embarrassment at the time of symptom onset. [Cancer Medicine 2020, doi: 10.1002/cam4.2953]

“Despite similar presentation and treatment strategies for breast cancer between both sexes, men fare infamously worse, with reported 5-year survival rates of only 40–65 percent. The main reason for this, as demonstrated by our data and numerous others’, is advanced staging at diagnosis,” highlighted the authors. [Lancet 2006;367:595-604; Crit Rev Oncol Hematol 2010;73:141-155]

All but one of the patients initially presented with a painless lump, while the remaining patient had an incidental finding of breast lump by a general practitioner during chest auscultation. Median tumour size was 23 mm (range, 2–100 mm). “Breast cancer in men is similar to breast cancer in women. It presents with a palpable mass, same types of tumour histology, and responds to similar treatment,” wrote the authors.

The 56 male patients treated at one breast cancer centre in Hong Kong between January 1998 and December 2018 accounted for 0.88 percent of all breast cancers treated during the same period. “Breast cancers in men are not as uncommon as they are perceived. They comprise 1 percent of all breast cancer, with a rising incidence,” wrote the researchers. [Lancet 2006;367:595-604]

Of the 36 survivors (64.3 percent of the original cohort), 31 (86.1 percent of survivors) agreed to a telephone interview. Eighteen (58 percent) of the interviewed patients reported experiencing “very” to “extremely” severe embarrassment (Likert score, 4–5 out of 5) at the time of symptom onset, while 11 patients (35.5 percent) experienced mild to moderate embarrassment (Likert score, 2–3). Only two patients (6.5 percent) experienced no embarrassment at all.

“More than 90 percent of our patients experienced various degrees of embarrassment at the time of breast symptom onset. All these individuals admitted that these negative feelings led to hesitation in seeking medical attention,” noted the researchers.

Over 90 percent of patients reported feeling uneasy in the waiting halls surrounded by exclusively female patients. “Psychosocial and emotional support is crucial to these marginalized men,” stated the researchers.

A quarter of patients (n=8; 25.8 percent) never talked to anyone about their symptoms prior to medical consultation, while 19 (61.3 percent) turned to their spouses. “Proactive partners encouraged men to seek help early, while good spousal relationship provided good psychosocial support,” noted the researchers.

Most patients (83.9 percent) were not aware that breast cancer can occur in men before their diagnosis. “Development of a proper media initiative to increase public understanding of male breast cancer is of outmost importance,” advised the authors. “Current breast cancer pamphlets are geared towards women – decorated in pink and illustrated with female anatomy. Improvements should be made in creating gender-specific information.”

Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 5 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.